Pro und Kontra: Monotherapie - Goldstandard der Psychopharmakabehandlung?

doi:10.1055/s-2006-939989

Psychiatrische Praxis, Table of Contents

Psychiatr Prax 2006; 33(5): 207-210
DOI: 10.1055/s-2006-939989

Debatte

Pro und Kontra: Monotherapie - Goldstandard der Psychopharmakabehandlung?

For and Against: Is Monotherapy the Gold Standard of Psychopharmacology?

Abstract

Full Text

References

Literatur

1 Stahl S M, Grady M M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem. 2004; 11 313-327
2 Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005; 5 26
3 Hunter R H, Joy C B, Kennedy E, Gilbody S M, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003 2 CD000440
4 Joy C B, Adams C E, Lawrie S M. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 2001 2 CD003082
5 Duggan L, Fenton M, Dardennes R M, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2003 1 CD001359
6 Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004 2 CD000967
7 Rummel C, Hamann J, Kissling W, Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev 2003 4 CD004410
8 Bitter I, Czobor P, Dossenbach M, Volavka J. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). Eur Psychiatry. 2005; 20 403-408
9 Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry. 2005; 66 1021-1030
10 Belgamwar R B, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev 2005 18 CD003729
11 Agid O, Kapur S, Arenovich T, Zipursky R B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003; 60 1228-1235
12 Leucht S, Busch R, Hamann J, Kissling W, Kane J M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005; 57 1543-1549
13 Lieberman J A, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer R M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003; 28 995-1003
14 McQuade R D, Stock E, Marcus R, Jody D, Gharbia N A, Vanveggel S, Archibald D, Carson W H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004; 65, Suppl 18 47-56
15 Freudenreich O, Goff D C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002; 106 323-330
16 Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl. 1992; 17 54-59
17 Davis J M. The choice of drugs for schizophrenia. N Engl J Med. 2006; 354 518-520
18 Josiassen R C, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing W W, Shaughnessy R A. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005; 162 130-136
19 Anil Y agcioglu, Kivircik A kdede, Turgut T I, Tumuklu M, Yazici M K, Alptekin K, Ertugrul A, Jayathilake K, Gogus A, Tunca Z, Meltzer H Y. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005; 66 63-72
20 Honer W G, Thornton A E, Chen E Y, Chan R C, Wong J O, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna P J, Stip E, Williams R, MacEwan G W, Wasan K, Procyshyn R. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006; 354 472-482
21 Hnasko T S, Sotak B N, Palmiter R D. Morphine reward in dopamine-deficient mice. Nature. 2005; 438 854-857
22 Tebartz van Elst L, Valerius G, Büchert M, Thiel T, Rüsch N, Bubl E, Hennig J, Ebert D, Olbrich H M. Increased prefrontal and hippocampal Glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry. 2005; 58 724-730
23 Bechter K. Mild encephalitis underlying psychiatric disorder - A reconsideration and hypothesis exemplified on Borna disease. Neurol Psychiatry Brain Res. 2001; 9 55-70
24 Maes M, Meltzer H Y, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 1994; 89 346-351
25 Davis K L, Stewert D G, Friedman J I, Buchsbaum M, Harvey P D, Hof P R, Buxbaum J, Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003; 60 441
26 Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel R R, Möller H J, Schwarz M J. Beneficial antipsychotic effect of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002; 159 1029-1034
27 Capuron L, Miller A H. Cytokines and psychopathology: lessons from interferon-α. Biol Psychiatry. 2004; 56 819-824
28 Haas H S, Schauenstein K. Neuroimmunomodulation via limbic structures: The neuroanatomy of psychoimmunology. Prog Neurobiol. 1997; 51 195-222
29 O'Connell P J, Wang X, Leon-Ponte M, Griffiths C, Pingle S C, Ahern G P. A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood. 2006; 107 1010-1017
30 Raison C L, Capuron L, Miller A H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006; 27 24-31
31 Banati R B. Microglia in psychiatric disease. World J of Biol Psychiatry. 2005; 6, Suppl 1 S62-63
32 Coull J AM, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter M W, Koninck Y De. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005; 438 1017-1021
33 Torsney C, MacDermott A B. A painful factor. Nature. 2005; 438 923-925
34 Messer T, Tiltscher C, Schmauss M. Polypharmazie in der Behandlung der Schizophrenie. Fortschr Neurol Psychiat. 2005; DOI: 10.1055/s-2005-915576
35 Kovess V, Caldas de Almeida José M, Carta M, Dubuis J, Lacalmontie E, Pellet J. et al . Professional team's choices of intervention towards problems and needs of patients suffering from schizophrenia across six European countries. Eur Psychiatry. 2005; 20 521-528
36 Stiegler M, Rummel C, Wahlbeck K, Kissling W, Leucht S. European psychiatric treatment guidelines: is the glass half full or half empty?. Eur Psychiatry. 2005; 20 554-558
37 Bloch S. The art of psychiatry. World Psychiatry. 2005; 4 130-134
38 Liebermann J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353 1209-1223
39 Reichmann H. Medikamentöse Parkinson-Therapie. Nervenarzt. 2005; 76 1547-1558
40 Gitlin M. Treatment resistant bipolar disorder. Mol Psychiatry. 2006; 11 227-240